logo
Grant Award from GHIT Fund for Development of an Ultrasensitive Urine Test for Tuberculosis

Grant Award from GHIT Fund for Development of an Ultrasensitive Urine Test for Tuberculosis

Business Wire23-04-2025
TOKYO--(BUSINESS WIRE)--H.U. Group Holdings, Inc. and its wholly-owned subsidiary Fujirebio Holdings, Inc. today announced that the Global Health Innovative Technology (GHIT) Fund has awarded a two-year, approximately $4.5 million grant to Fujirebio's wholly-owned subsidiary, Fluxus, Inc. (Location: Sunnyvale, California), to develop an ultrasensitive point-of-care (POC) urine test for tuberculosis (TB). The test will utilize Fluxus' novel single-molecule counting technology, with the potential to be used for both pulmonary and extrapulmonary TB in all patient populations.
According to the World health Organization (WHO)* 1, up to two million people die from TB each year, making it one of the leading causes of infectious disease death worldwide. Diagnostic tests are typically performed in sputum, a sample type that is difficult to collect and which severely limits the types of TB and patient populations that can be tested. A sensitive, accurate, and accessible non-sputum-based test is urgently needed to reduce the global burden of TB.
The new POC test will measure lipoarabinomannan (LAM), a TB biomarker in urine. Fluxus currently has an ultrasensitive LAM assay prototyped on its benchtop analyzer platform* 2. The GHIT award will fund development towards the launch of the POC instrument and adaptation of the LAM assay to POC test format. The work will be done by Fluxus in partnership with Rapid Research in Diagnostics Development (R2D2) for TB Network, as represented by Heidelberg University Hospital, and Stanford University and Health Care.
This grant enables Fujirebio to further contribute to addressing global health needs and delivering critical improvements in access to healthcare.
*1 WHO. Global Tuberculosis Report 2023, issued on November 7, 2023
*2 https://academic.oup.com/ofid/article/12/Supplement_1/ofae631.974/7987127#google_vignette
The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world's vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Don't eat these potentially radioactive shrimp, FDA warns
Don't eat these potentially radioactive shrimp, FDA warns

Los Angeles Times

time38 minutes ago

  • Los Angeles Times

Don't eat these potentially radioactive shrimp, FDA warns

The U.S. Food and Drug Administration is warning people to avoid eating certain raw frozen shrimp sold in Walmart stores as the agency investigates possible contamination by Cesium-137, a radioactive isotope. U.S. Customs and Border Protection alerted the FDA to the detection of Cesium-137 in a single shipment of imported frozen shrimp from the Indonesia-based company PT. Bahari Makmur Sejati, which does business under the name BMS Foods. Officials have since detected the radioactive isotope at four ports across the nation: Los Angeles, Houston, Miami; and Savannah, Ga. The amount of Cesium-137 detected within the contaminated shipment would not pose an acute hazard to consumers. However, long-term consumption would pose an elevated risk of cancer. Bags of the frozen food product are sold under the brand name Great Value at Walmart stores in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. All containers and products that tested positive or alerted for Cesium-137 have been denied entry into the country, according to an FDA announcement on Tuesday. Federal officials are coordinating with Indonesian seafood regulatory authorities to investigate the root cause of the contamination. There have not been any reports of contaminated shrimp in the freezer section or within the U.S. food supply chain, authorities said. Cesium-137 can be found in soil, food and air, according to the Environmental Protection Agency. It is produced by nuclear fission for use in medical gauges and devices, but can also be a byproduct of nuclear reactors and weapons testing, the agency said. Though bags of frozen shrimp haven't tested positive for Cesium-137, officials say the product may have been prepared, packed or held in unsanitary conditions. Walmart has received shipments of the frozen food that were imported after the date of the first detection, but those specific shipments did not alert for contamination, officials said. Shoppers who purchased the following products should not consume eat or serve the frozen shrimp, but instead throw it away, authorities say: The FDA is currently recommending that Walmart completely recall the item. BMS Foods is also no longer allowed to import the products into the U.S. until the company addresses any potential issues.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store